Back

Evolution of low risk natriuretic peptide to higher risk - Do we have a phenotype?

25 May 2019 (11:38 - 11:43)
Organised by:
Congress Presentation Part of: Rapid Fire 2 - Biomarker: present and future Prevention HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Nial Blake

Mater Private Hospital, Dublin (Ireland)

10 More presentations in this session

Presentation thumbnail
Role of neprilysin in myocardial tissue Renin-Angiotensin-System (RAS) of the failing heart
Doctor N. Pavo (Vienna, AT)
Abstract
Presentation thumbnail
The value of tubular maximum phosphate reabsorption capacity, a functional proximal tubular parameter in heart failure
Ms L. Emmens (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
The risk of bias of current novel circulating biomarker studies for the detection of HFpEF and left ventricular diastolic dysfunction
Mr M. Henkens (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients
Doctor R. Nielsen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Improvement of existing strategies to prevent heart failure after myocardial infarction: a potential role for thrombopoietin
Associate Professor L. Malinova (Saratov, RU)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire 2 - Biomarker: present and future

The Event

Event poster

Heart Failure 2019

25 May 2019 11:38 CET
You may be interested in
thumbnail
Congress Session
The strength of scientific integration
thumbnail
Congress Session
Which device might help your HFpEF patient?
thumbnail
Congress Session
Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives